We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.18% | 28.00 | 27.50 | 28.10 | 27.95 | 27.80 | 27.95 | 805,775 | 16:35:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -252.73 | 187.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/10/2018 09:23 | Delayed buys being printed now | imjustdandy | |
31/10/2018 08:21 | Berny AGAIN Conveniently - joint cost sharing, if you read the deatail. | macangts | |
31/10/2018 08:18 | Bought some back it's fallen a long way recently | dave4545 | |
31/10/2018 07:56 | Good try Mac. They said in the recent presentation they will not be spending any more money on drug development instead concentrating on its core business of conducting trials for pharmas. In any case they got a grant to do the AGS-V trial which you probably already know but conveniently failed to mention. This is from the 2017 half year report: "Public health grants awarded to hVIVO from US DARPA (Defense Advanced Research Projects Agency) for a flu contagiousness R&D project and to Imutex from the UK's innovation agency, Innovate UK, for further development of AGS-v (£3.0 million), both post period end." | bernymadoff | |
31/10/2018 07:46 | Given the safety profile of the vaccine observed in this study further development of the vaccine will continue. For above READ Despite our previous announcement that the new business model will be cash generative in 2019 - we will need further cash to support the continued development. | macangts | |
31/10/2018 07:45 | So HVO's JV company Imutex now has two potential blockbuster drugs at different stages of development. Flu-V has already met Phase 2 endpoints and is the subject of commercialisation talks with major pharmas. I expect we will hear something on that front soon enough. Ags-V is the new kid on the block. Again it's potential is enormous. According to the World Health Organisation WHO, nearly 50% of the global population is at the risk of malaria. There were 214 million malaria cases reported in 2015. Great initial P1 results will only increase the appeal of a takeover of Imutex by the majors. Over the moon with this update. | bernymadoff | |
31/10/2018 07:27 | 80m shares in issue Just 25% in free float HVO is going to be one hell of a performer going forward. They now have a promising anti-malaria vaccine too. It's being developed by the same JV company Imutex which developed Flu-v and if you look at the Hvivo company presentation that accompanied the recent interims they have put a "for sale" sign up for the whole company/platform. Hvivo own 49% of Imutex. | bernymadoff | |
31/10/2018 07:19 | Let us pray the other clowns here are getting burnt today. | discojames | |
31/10/2018 07:12 | RNS out.....Boom! Now they not only have the world's most advanced universal flu vaccine candidate which is the subject of commercialisation talks with the majors, they also have a potential blockbuster anti-malaria drug in development. These initial readings for AGS-v are extremely positive!! Hope you've all been loading up on the cheap. I bought again at 42.5 last week! | bernymadoff | |
30/10/2018 06:41 | what they are doing is not unique. the only 'fool' who 'scrambled in' is you and now you are bitter and sitting on a hefty loss | mister md | |
29/10/2018 22:05 | Plenty of majors will be talking with us at the moment as you well know you chancer. Just because nothing has been announced yet doesn't mean things aren't moving behind the scenes. By their nature commercial negotiations are low key and secretive affairs. Just be sure that when they do RNS a deal or MOU you'll be scrambling to buy in at multiples of today's share price and crying in your corn flakes. Fool | bernymadoff | |
29/10/2018 20:25 | was that your sell at 40p today ? This is a loss-making company with a 35 M marketcap - how come no Major pharma is getting involved yet after all the hype ? | mister md | |
29/10/2018 17:14 | I see you've stopped deramping on Yu Group now that's going back up. No doubt it'll be the same here. | bernymadoff | |
27/10/2018 09:44 | thats what you also said at 50p, its dropped another 13% since bernymadoff - 17 Oct 2018 - 13:44:48 - 1991 of 2017 If it's any guide the last time the share price was at 50p it promptly went on to do over 100%. Just saying | mister md | |
26/10/2018 11:42 | Look at the chart. Last time it touched this level it shot up to 110p | bernymadoff | |
26/10/2018 11:25 | Bottom is in I reckon. Technically it is massively oversold wirh RSI on the floor and Stoch turning upwards. Just seen a couple of buys come in too | bernymadoff | |
26/10/2018 07:19 | good advice, cash is king after all... but think I will hold on to my sensible portfolio thanks | mister md | |
25/10/2018 22:14 | Little kid playing in a big market! Something you can't handle! Keep your penny's in your pocket! | spurs777 | |
25/10/2018 18:40 | buy some more then, clueless tw@ts (though I suspect you are the same poster) | mister md | |
25/10/2018 15:29 | read the glassdoor reviews, worse than any on any other company | mister md | |
25/10/2018 15:10 | What do you want a Blue Peter badge? Can't believe how sad some people are that they have to continually post about their wins | bernymadoff | |
25/10/2018 14:06 | Now at half the price I sold at. Is Berny averaging down again ? | mister md |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions